Bavarian Nordic A/S (BAVA.CO)
- Previous Close
173.35 - Open
178.00 - Bid 178.35 x --
- Ask 178.60 x --
- Day's Range
176.60 - 183.00 - 52 Week Range
125.55 - 222.00 - Volume
894,501 - Avg. Volume
575,074 - Market Cap (intraday)
13.933B - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
14.19 - EPS (TTM)
12.60 - Earnings Date Feb 21, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
267.29
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
www.bavarian-nordic.comRecent News: BAVA.CO
Performance Overview: BAVA.CO
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BAVA.CO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BAVA.CO
Valuation Measures
Market Cap
13.93B
Enterprise Value
11.77B
Trailing P/E
14.19
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.08
Price/Book (mrq)
1.37
Enterprise Value/Revenue
1.77
Enterprise Value/EBITDA
7.00
Financial Highlights
Profitability and Income Statement
Profit Margin
14.82%
Return on Assets (ttm)
7.85%
Return on Equity (ttm)
10.20%
Revenue (ttm)
6.64B
Net Income Avi to Common (ttm)
984.37M
Diluted EPS (ttm)
12.60
Balance Sheet and Cash Flow
Total Cash (mrq)
2.29B
Total Debt/Equity (mrq)
1.31%
Levered Free Cash Flow (ttm)
1.72B
Research Analysis: BAVA.CO
Company Insights: BAVA.CO
BAVA.CO does not have Company Insights